Oncobiologics Announces Term Extension of Series A Warrants
February 06 2017 - 4:10PM
Oncobiologics, Inc. (Nasdaq:ONS) (Nasdaq:ONSIW), a clinical-stage
biopharmaceutical company focused on identifying, developing,
manufacturing and commercializing complex monoclonal antibody
biosimilar therapeutics, today announced an extension to the term
for exercise of its publicly traded Series A warrants
(NASDAQ:ONSIW).
The Series A warrants were issued as part of the
units in Oncobiologics’ May 2016 initial public offering and are
exercisable for shares of its common stock at an exercise price of
$6.60 per share. The Series A warrants would have expired at 5:00
pm New York City time on February 18, 2017. The expiration date has
now been extended to 5:00 p.m. New York City time on February 18,
2018. The Series A warrants and the common stock issuable upon
exercise of the Series A warrants are covered by a registration
statement on Form S-1, as amended, previously filed with and
declared effective by the Securities and Exchange Commission.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful, prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Oncobiologics, Inc. and its
BioSymphony™ PlatformOncobiologics is a clinical-stage
biopharmaceutical company focused on identifying, developing,
manufacturing and commercializing complex biosimilar therapeutics.
Its current focus is on technically challenging and commercially
attractive monoclonal antibodies (mAbs) in the disease areas of
immunology and oncology. Oncobiologics is advancing its pipeline of
eight biosimilar products, two of which are currently in clinical
development. Led by a team of biopharmaceutical experts,
Oncobiologics operates from an in-house state-of-the-art fully
integrated research and development, and manufacturing facility in
Cranbury, New Jersey. Oncobiologics employs its BioSymphony™
Platform to address the challenges of biosimilar development and
commercialization by developing high quality mAb biosimilars in an
efficient and cost-effective manner on an accelerated timeline. For
more information, please visit www.oncobiologics.com.
CONTACTS:
Oncobiologics:
Lawrence A. Kenyon
Chief Financial Officer
LawrenceKenyon@oncobiologics.com
Media & Investors:
Alex Fudukidis
Russo Partners, LLC
alex.fudukidis@russopartnersllc.com
Oncobiologics Series A Warrant Expiring 2/18/2019 (delisted) (NASDAQ:ONSIW)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncobiologics Series A Warrant Expiring 2/18/2019 (delisted) (NASDAQ:ONSIW)
Historical Stock Chart
From Apr 2023 to Apr 2024